Brexit: Companies Must ‘Act Now’ To Avoid Drug Supply Disruptions In 2021
First Ferry Tickets About To Be Released
In its latest letter to medicines and medical product companies, the UK's Department of Health and Social Care says the biggest potential cause of disruption to supplies could be failure to prepare for border controls implemented by the EU member states after the end of the Brexit transition period.
You may also be interested in...
EU-UK Trade Deal Allows For Mutual Recognition Of GMP Inspections
The trade deal agreed by the EU and the UK may have brought some relief to the life sciences sector in that it averts the chaos that would have followed failure to reach a deal, but it contains little that will have a direct impact on the regulation of medicines.
Life Science Sector Still In The Dark As UK-EU Trade Talks Make Progress
Hope is not lost as the EU sees a "narrow path" to a trade deal with the UK, but the life sciences industry is still facing uncertainty over key issues such as medicines batch testing.
Brexit: The View For Pharma In 2021 And Beyond
With the end of the Brexit transition period fast approaching, life sciences companies need to be ready for some major changes to drug regulations as well as the impact of new border and customs controls on the flow of medicines between Great Britain, Northern Ireland and the EU. In Vivo looks at what is at stake, and what still needs to be done, as the UK prepares to leave the EU single market and customs union at the beginning of 2021.